4-HO-MiPT
| Clinical data | |
|---|---|
| Other names | 4-OH-MiPT; 4-Hydroxy-N-methyl-N-isopropyltryptamine; Miprocin |
| Routes of administration | Oral |
| Drug class | Non-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Onset of action | 10–20 minutes |
| Duration of action | 4–6 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H20N2O |
| Molar mass | 232.327 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 123 to 125 °C (253 to 257 °F) |
| |
| |
| (verify) | |
4-HO-MiPT, also known as 4-hydroxy-N-methyl-N-isopropyltryptamine or as miprocin, is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families related to psilocin (4-HO-DMT). It appears to be similar to psilocin in terms of onset, duration, and effects. The drug is taken orally.
It acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor among others. The drug is closely related structurally to MiPT, 4-HO-DiPT, and psilocin (4-HO-DMT).
4-HO-MiPT was first described in the literature by David Repke and colleagues in 1981. Its effects in humans were subsequently described by Repke and Alexander Shulgin in 1985 and 1997. The drug was first encountered as a novel designer drug by 2010.
Category:
- Drugs not assigned an ATC code